December 02, 2020
Updated December 3 with new information
Dallas — Medical City Healthcare now offers Bamlanivimab monoclonal antibody infusions, on a very limited basis, to patients who have tested positive for COVID-19 and have other high-risk factors.
The FDA has authorized the emergency use of Bamlanivimab for the treatment of COVID-19 under an Emergency Use Authorization (EUA). The therapy is intended for treatment of mild to moderate positive COVID-19 adult and pediatric patients over the age of 12 who are high risk to develop severe COVID-19. High-risk conditions that may be eligible for this treatment include:
- Chronic kidney disease
- Immunosuppressive disease
- Heart disease
In children, sickle cell disease, neurodevelopmental disorders and asthma are also among several additional considerations for eligibility.
“Medical City Healthcare is committed to excellent patient care and offering this monoclonal antibody treatment can help make a meaningful impact in the fight against COVID-19,” says Miguel Benet, MD, division chief medical officer. “As part of HCA Healthcare, one of the nation’s leading providers of healthcare, we have the resources to provide support and solutions to our patients, colleagues and communities, including the latest approved treatments for COVID-19.”
Medication supply is limited and administered based upon availability. Patients must obtain a referral from a Medical City Healthcare physician. Patients who meet the criteria for treatment will be referred for outpatient treatment at infusion centers located at Medical City Dallas and Medical City Fort Worth. Patients eligible for therapy will receive one dose by intravenous infusion over the course of one hour.
Bamlanivimab is not authorized for use for patients who:
- Are hospitalized due to COVID-19
- Require oxygen therapy due to COVID-19
- Require oxygen due to another underlying medical condition
To find more updates and learn more about safety measures at Medical City Healthcare facilities, visit the Coronavirus Resource Hub.